Home / Stocks / BTMD

biote (BTMD, Pharmaceuticals) Stock Valuation & Fair Value Fairly valued

biote (BTMD, Pharmaceuticals) trades at a blended P/E of 6.5, about 82% below its historical normal valuation, with a forward growth estimate of -15.8%. Priced at its historical normal P/E of 36.7 on the same blended earnings, the 2026-09-18 close of $1.36 corresponds to about $7.74 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
6.5
Normal P/E
36.7
PEG
—
Fwd growth
-15.8%
Div yield
0.0%
RSI (14)
38.1
Neutral

The Street vs SeerForecast

Wall Street's mean price target for BTMD is $2.61 across 5 analysts, 100.9% above the current price. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from quality business with a solid forward outlook (2026-07-31) to fairly valued (2026-09-21).

Blended P/E and rating by weekBlended P/E moved from 4.3 to 6.5 between 2026-07-31 and 2026-09-21, against a normal P/E of 36.7, with 3 rating changes over 18 recorded weeks.2026-07-31: P/E 4.3, Quality business with a solid forward outlook (recalculated)2026-08-03: P/E 4.3, Quality business with a solid forward outlook2026-08-07: P/E 4.3, Quality business with a solid forward outlook (recalculated)2026-08-10: P/E 3.9, Fairly valued2026-08-14: P/E 3.9, Fairly valued (recalculated)2026-08-17: P/E 4.3, Quality business with a solid forward outlook2026-08-21: P/E 4.3, Quality business with a solid forward outlook (recalculated)2026-08-24: P/E 6.0, Fairly valued2026-08-27: P/E 6.0, Fairly valued (recalculated)2026-08-28: P/E 6.0, Fairly valued (recalculated)2026-08-30: P/E 6.0, Fairly valued (recalculated)2026-08-31: P/E 6.2, Fairly valued2026-09-05: P/E 6.2, Fairly valued (recalculated)2026-09-07: P/E 6.5, Fairly valued2026-09-12: P/E 6.5, Fairly valued (recalculated)2026-09-14: P/E 5.9, Fairly valued2026-09-19: P/E 5.9, Fairly valued (recalculated)2026-09-21: P/E 6.5, Fairly valued10.020.030.0Jul 31Aug 13Aug 26Sep 8Sep 21Normal P/E 36.7
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 4.3-88%Quality business with a solid forward outlook
2026-08-10P/E 3.9-89%Fairly valued
2026-08-17P/E 4.3-88%Quality business with a solid forward outlook
2026-08-24P/E 6.0-84%Fairly valued
2026-09-07P/E 6.5-82%Fairly valued
2026-09-21P/E 6.5-82%Fairly valued ← now

Frequently asked questions

Is biote stock overvalued?

At a blended P/E of 6.5 versus its historical normal P/E of 36.7, biote trades about 82% below its typical valuation. tickerseer currently rates it fairly valued.

What is biote's fair value and PEG?

biote trades at a blended P/E of 6.5 against a historical normal P/E of 36.7, a forward growth estimate of -15.8%. Priced at its historical normal P/E of 36.7 on the same blended earnings, the 2026-09-18 close of $1.36 corresponds to about $7.74 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of biote changed?

tickerseer's rating moved from quality business with a solid forward outlook (2026-07-31) to fairly valued (2026-09-21).

What is the analyst price target for biote?

The mean Wall Street price target for biote is $2.61 across 5 analysts, 100.9% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track BTMD free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.